Clinical Trials
2 trialsNCT04225390 2026-02-10
PROMIT
University of Erlangen-NĂŒrnberg Medical School
Phase 2 Completed
NCT05223088 2025-03-18
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IVăLarge Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Completed